论文部分内容阅读
通过亚慢性动物实验研究了新型络合剂４－甲氧苄基－Ｄ－葡糖胺－Ｎ－二硫代羧酸钠（ＭｅＯＢＧＤＴＣ）对尿镉排泄及组织脏器中镉含量的影响。先给大鼠腹腔注射４．４４８μｍｏｌＣｄ２＋／ｋｇｄ的氯化镉，每周５次，共４周。然后腹腔注射８８９．６００μｍｏｌ／ｋｇｄ的ＭｅＯＢＧＤＴＣ，每周５次，间隔１周为１个疗程，共两个疗程。结果表明：能显著增加大鼠的尿镉排泄量，且可持续至第１０个给药日，分别是单纯染镉组的１．４０～３．３３倍。尿镉排泄水平随给药次数的增加而逐渐降低。ＭｅＯＢＧＤＴＣ还能明显降低大鼠血液及肝、肾等组织中的镉负荷。
The effects of MeOBGDTC, a new complexing agent, on cadmium excretion and cadmium content in tissues and organs were studied by subchronic animal experiments. The rats were given intraperitoneal injection of cadmium chloride 4.448μmol Cd2 + / kgd 5 times a week for 4 weeks. Then intraperitoneal injection of 889.600μmol / kgd of MeOBGDTC, 5 times a week, 1 week interval for a course of treatment, a total of two courses. The results showed that: can significantly increase urinary cadmium excretion in rats, and can last until the 10th administration day, respectively, with cadmium group was 1.40 to 3.33 times. Urinary cadmium excretion decreased gradually with the increase of administration frequency. MeOBGDTC also significantly reduced the cadmium load in the blood and liver, kidney and other tissues in rats.